Becoming an investigative journalist is a rewarding journey. It involves uncovering hidden truths and holding power to account. This guide will help you start your path in investigative journalism, ...

2025 Free Cash Flow Guidance: $1.6 billion to $1.9 billion. Teva Pharmaceutical Industries Ltd (NYSE:TEVA) reported a 9% increase in revenue for 2024, reaching $16.5 billion, driven by strong ...

Teva Pharmaceutical Industries' Q4 2024 results were strong, but 2025 guidance underwhelmed, causing a sharp stock sell-off. Management's cautious 2025 guidance sets a low bar, likely to be ...

Teva reported growth for the second year in a row. Despite exceeding Wall Street targets, the company's guidance came up short. Teva reported earnings before trading began on Wednesday. The ...

Shares of Teva Pharmaceutical Industries (NYSE: TEVA) were slipping Wednesday. The company's stock lost 13.5% as of 1:15 p.m. ET. The leg down comes as the S&P 500 (SNPINDEX: ^GSPC) and Nasdaq ...

Teva Pharmaceutical reports fourth-quarter revenue of $4.2 billion, beating analyst estimates of $4.13 billion. Teva reports fourth-quarter adjusted earnings of 71 cents per share, beating ...

JERUSALEM, Jan 29 (Reuters) - Teva Pharmaceutical Industries (TEVA.TA), opens new tab reported a slightly larger than expected rise in fourth-quarter profit, helped by double-digit sales gains in ...

The FDA has accepted Alvotech (NASDAQ:ALVO) and Teva's (NYSE:TEVA) Biologics License Applications for AVT05, their proposed biosimilar to the anti-inflammatory drugs Simponi and Simponi Aria.